Float Short %

13.28

Margin Of Safety %

Put/Call OI Ratio

0.33

EPS Next Q Diff

EPS Last/This Y

0.57

EPS This/Next Y

0.43

Price

7.95

Target Price

16.64

Analyst Recom

1.18

Performance Q

-8.73

Relative Volume

1.76

Beta

1.1

Ticker: BCRX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-07	BCRX	8.76	0.34	0.53	30742
2025-07-08	BCRX	8.79	0.34	0.07	30802
2025-07-09	BCRX	9.06	0.34	0.02	30960
2025-07-10	BCRX	8.89	0.34	0.00	31004
2025-07-11	BCRX	8.76	0.33	0.07	30856
2025-07-14	BCRX	8.98	0.33	0.00	30971
2025-07-15	BCRX	8.72	0.32	0.17	31036
2025-07-16	BCRX	8.58	0.32	0.54	31100
2025-07-17	BCRX	8.71	0.32	0.08	31260
2025-07-18	BCRX	8.61	0.32	0.04	31463
2025-07-21	BCRX	8.52	0.32	0.00	29674
2025-07-22	BCRX	8.66	0.32	0.16	29905
2025-07-23	BCRX	8.62	0.31	0.00	30383
2025-07-24	BCRX	8.56	0.31	4.85	30451
2025-07-25	BCRX	8.56	0.34	0.00	31169
2025-07-28	BCRX	8.27	0.34	0.08	31323
2025-07-29	BCRX	8.09	0.34	0.08	31568
2025-07-30	BCRX	8.23	0.33	0.08	31663
2025-07-31	BCRX	8.14	0.33	0.05	31774
2025-08-01	BCRX	7.95	0.33	0.78	32188
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-07	BCRX	8.76	138.3	-	0.14
2025-07-08	BCRX	8.79	138.3	-	0.14
2025-07-09	BCRX	9.06	138.3	-	0.14
2025-07-10	BCRX	8.88	138.3	-	0.14
2025-07-11	BCRX	8.76	138.3	-	0.14
2025-07-14	BCRX	8.97	138.3	-	0.14
2025-07-15	BCRX	8.72	138.3	-	0.14
2025-07-16	BCRX	8.59	138.3	-	0.14
2025-07-17	BCRX	8.70	138.3	-	0.14
2025-07-18	BCRX	8.61	138.3	-	0.14
2025-07-21	BCRX	8.52	138.3	-	0.14
2025-07-22	BCRX	8.67	138.3	-	0.14
2025-07-23	BCRX	8.61	138.3	-	0.14
2025-07-24	BCRX	8.55	145.0	-	0.14
2025-07-25	BCRX	8.55	145.0	-	0.14
2025-07-28	BCRX	8.23	143.1	-	0.14
2025-07-29	BCRX	8.09	143.1	-	0.14
2025-07-30	BCRX	8.22	143.1	-	0.14
2025-07-31	BCRX	8.14	143.1	-	0.14
2025-08-01	BCRX	7.95	143.1	-	0.14
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-07	BCRX	0.00	5.66	11.52
2025-07-08	BCRX	0.00	5.66	11.52
2025-07-09	BCRX	0.00	5.66	11.52
2025-07-10	BCRX	0.00	5.66	11.52
2025-07-11	BCRX	0.00	5.66	13.59
2025-07-14	BCRX	0.00	6.10	13.50
2025-07-15	BCRX	0.00	6.10	13.50
2025-07-16	BCRX	0.00	6.10	13.50
2025-07-17	BCRX	0.00	6.10	13.50
2025-07-18	BCRX	0.00	6.10	13.50
2025-07-21	BCRX	0.00	8.23	13.50
2025-07-22	BCRX	0.00	8.23	13.50
2025-07-23	BCRX	0.00	8.23	13.50
2025-07-24	BCRX	0.00	8.23	13.50
2025-07-25	BCRX	0.00	8.23	13.28
2025-07-28	BCRX	0.00	7.68	13.28
2025-07-29	BCRX	0.00	7.68	13.28
2025-07-30	BCRX	0.00	7.68	13.28
2025-07-31	BCRX	0.00	7.68	13.28
2025-08-01	BCRX	0.00	7.68	13.28
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.03

Avg. EPS Est. Next Quarter

0.05

Insider Transactions

Institutional Transactions

7.68

Beta

1.1

Average Sales Estimate Current Quarter

147

Average Sales Estimate Next Quarter

156

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

60.2

Max Drawdown 5-Year %

-79.1

Target Price

16.64

P/E

Forward P/E

16.75

PEG

P/S

3.3

P/B

P/Free Cash Flow

EPS

-0.26

Average EPS Est. Cur. Y

0.14

EPS Next Y. (Est.)

0.57

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-10.62

Relative Volume

1.76

Return on Equity vs Sector %

-11.9

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

BioCryst Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 580

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

stock quote shares BCRX – BioCryst Pharmaceuticals, Inc. Stock Price stock today

news today BCRX – BioCryst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BCRX – BioCryst Pharmaceuticals, Inc. yahoo finance google finance

stock history BCRX – BioCryst Pharmaceuticals, Inc. invest stock market

stock prices BCRX premarket after hours

ticker BCRX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BCRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y